You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommends Opdivo as post-surgery treatment

Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Opdivo (nivolumab) for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma (MIUC).